Cited 0 times in Scipus Cited Count

Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.

DC Field Value Language
dc.contributor.authorOh, SY-
dc.contributor.authorKim, DY-
dc.contributor.authorKim, YB-
dc.contributor.authorSuh, KW-
dc.date.accessioned2014-05-27T05:03:00Z-
dc.date.available2014-05-27T05:03:00Z-
dc.date.issued2013-
dc.identifier.issn0364-2313-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/10185-
dc.description.abstractBACKGROUND: Little is known of the oncological outcomes after adjuvant FOLFOX chemotherapy in patients with stage III colon cancer showing microsatellite instability high (MSI-H). In the present study we investigated the prognostic impact of MSI-H in patients with stage III colon cancer receiving FOLFOX chemotherapy.



METHODS: We analyzed the MSI status in 127 patients with stage III colon cancer who underwent curative surgical resection followed by FOLFOX chemotherapy between January 2003 and December 2010. We assessed disease-free and overall survival (OS) in patients with MSI-H colon cancer compared with those showing microsatellite instability low or microsatellite stable (MSI-L/MSS) disease.



RESULTS: Sixteen of the patients (12.6 %) were MSI-H, and 111 patients (87.4 %) were MSI-L/MSS. There was no significant difference between patients showing MSI-H and MSI-L/MSS except for age (P = 0.030), tumor location (P < 0.001), and differentiation (P = 0.031). Compared with MSI-L/MSS colon cancer, patients with MSI-H colon cancer had no significant difference in 5-year disease-free and OS (72.2 vs 68.5 %, P = 0.874; 68.1 vs 71.1 %, P = 0.437).



CONCLUSIONS: Our study indicates that FOLFOX chemotherapy can be considered to treat stage III colon cancer patients with MSI-H after surgery, although the study was not randomized and included only a limited number of patients.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHColectomy-
dc.subject.MESHColonic Neoplasms-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHLeucovorin-
dc.subject.MESHMale-
dc.subject.MESHMicrosatellite Instability-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOrganoplatinum Compounds-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Outcome-
dc.titleOncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.-
dc.typeArticle-
dc.identifier.pmid23754140-
dc.contributor.affiliatedAuthor오, 승엽-
dc.contributor.affiliatedAuthor김, 도윤-
dc.contributor.affiliatedAuthor김, 영배-
dc.contributor.affiliatedAuthor서, 광욱-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s00268-013-2120-8-
dc.citation.titleWorld journal of surgery-
dc.citation.volume37-
dc.citation.number10-
dc.citation.date2013-
dc.citation.startPage2497-
dc.citation.endPage2503-
dc.identifier.bibliographicCitationWorld journal of surgery, 37(10). : 2497-2503, 2013-
dc.identifier.eissn1432-2323-
dc.relation.journalidJ003642313-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse